Mifepristone at SCOTUS: Justices "Skeptical" of Plaintiffs, Unlikely to Limit Pill's Availability

The Supreme Court heard oral arguments Tuesday on the abortion pill mifepristone, which is available by mail and can be taken at home, even in states that have severely limited or banned abortions. The case was brought by a group of anti-choice medical associations that have sought to overturn moves by the Food and Drug Administration to increase access to the drug, which is used for roughly two-thirds of all U.S. abortions. This was the first abortion-related Supreme Court hearing since the court overturned Roe v. Wade in 2022. A decision is expected by July. “Overall the justices showed that they were skeptical of the claims brought by the plaintiffs in this case,” says Michele Goodwin, a law professor at Georgetown University and founding director of the Center for Biotechnology and Global Health Policy. Goodwin summarizes the arguments presented by both sides, the justices’ responses and the legal implications of the upcoming ruling.